Barinthus Biotherapeutics plc (BRNS) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.38
↓-46% vs avg
5yr avg: 0.70
30Y Low0.4·High1.6
ROE
↓
-65.0%
↑-84% vs avg
5yr avg: -35.2%
30Y Low-65%·High2%
Debt/EBITDA
N/A
—
5yr avg: 31.11
30Y Low31.1·High31.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BRNS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Barinthus Biotherapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $29M | $28M | $48M | $142M | $90M | $413M | — | — |
| Enterprise Value | $-30670646 | $-30805947 | $-51043920 | $13M | $-95914850 | $206M | — | — |
| P/E Ratio → | -0.43 | — | — | — | 16.79 | — | — | — |
| P/S Ratio | — | — | 3.18 | 176.61 | 2.01 | 1541.68 | — | — |
| P/B Ratio | 0.38 | 0.38 | 0.37 | 0.76 | 0.37 | 1.64 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BRNS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -3.41 | 15.62 | -2.15 | 769.92 | — | — |
| EV / EBITDA | — | — | — | — | -340.12 | — | — | — |
| EV / EBIT | — | — | — | — | -110.37 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
BRNS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have expanded from -10463.1% to -454.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -65.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | -198.4% | -336.0% |
| Operating Margin | — | — | -454.1% | -10463.1% | -9.0% | -16873.5% | -415.8% | -374.9% |
| Net Profit Margin | — | — | -408.0% | -9145.5% | 11.9% | -18979.5% | -367.3% | -302.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -65.0% | -65.0% | -38.5% | -34.1% | 2.2% | -40.8% | — | — |
| ROA | -51.4% | -51.4% | -32.6% | -30.3% | 1.9% | -30.7% | -50.8% | -108.9% |
| ROIC | -174.5% | -174.5% | -114.1% | -109.0% | -5.9% | -148.5% | — | — |
| ROCE | -46.6% | -46.6% | -39.2% | -36.5% | -1.5% | -28.9% | -71.2% | -193.1% |
BRNS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $70M exceeds total debt of $11M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.09 | 0.07 | 0.04 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | 31.11 | — | — | — |
| Net Debt / Equity | — | -0.80 | -0.76 | -0.69 | -0.76 | -0.82 | — | — |
| Net Debt / EBITDA | — | — | — | — | -658.20 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -1060.16 | -1060.16 | -1154.23 | -2731.93 | 45.74 | -18.17 | -4.66 | -170.21 |
Net cash position: cash ($70M) exceeds total debt ($11M)
BRNS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Barinthus Biotherapeutics plc's current ratio of 7.77x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.45x to 7.77x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.77 | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 | 6.27 | 2.83 |
| Quick Ratio | 7.77 | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 | 6.27 | 2.83 |
| Cash Ratio | 7.03 | 7.03 | 7.07 | 11.28 | 15.88 | 19.18 | 5.66 | 1.99 |
| Asset Turnover | — | — | 0.09 | 0.00 | 0.17 | 0.00 | 0.10 | 0.36 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 316.94 | 3613.14 | 147.34 | 15956.49 | 39.22 | 208.38 |
BRNS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Barinthus Biotherapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 6.0% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $41M | $39M | $38M | $38M | $37M | $8M | $8M |
Peer Comparison
Compare BRNS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BRNSYou | $29M | -0.4 | — | — | — | — | -65.0% | -174.5% | — |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 NKTX | $200M | -2.0 | — | — | — | — | -28.9% | -22.5% | — |
 IMCR | $1B | -55.4 | — | — | 97.9% | -11.3% | -7.1% | -17.2% | — |
 ADCT | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 NVAX | $1B | 3.5 | 2.5 | — | 93.7% | 50.1% | — | — | 0.4 |
 IOVA | $1B | -3.7 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 FATE | $251M | -1.9 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 NUVB | $2B | -9.6 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 RCKT | $378M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 PACB | $410M | -0.7 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BRNS — Frequently Asked Questions
Quick answers to the most common questions about buying BRNS stock.
What is Barinthus Biotherapeutics plc's P/E ratio?
Barinthus Biotherapeutics plc's current P/E ratio is -0.4x. The historical average is 16.8x.
What is Barinthus Biotherapeutics plc's ROE?
Barinthus Biotherapeutics plc's return on equity (ROE) is -65.0%. The historical average is -35.2%.
Is BRNS stock overvalued?
Based on historical data, Barinthus Biotherapeutics plc is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.